RO 251553

Drug Profile

RO 251553

Latest Information Update: 19 Sep 2006

Price : $50

At a glance

  • Originator Roche
  • Class Antiasthmatics; Bronchodilators; Muscle relaxants; Peptides
  • Mechanism of Action Vasoactive intestinal peptide receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Asthma

Most Recent Events

  • 19 Sep 2006 Discontinued - Clinical-Phase-Unknown for Asthma in Sweden (unspecified route)
  • 19 Sep 2006 Discontinued - Preclinical for Asthma in USA (unspecified route)
  • 31 Jul 2003 A clinical study has been added to the pharmacodynamics and adverse events sections
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top